Cancer cells characterized by uncontrolled growth and proliferation require altered
metabolic processes to maintain this characteristic. Metabolic reprogramming is a process …

Besides fast glucose catabolism, many types of cancers are characterized by elevated
glutamine consumption. Medical oncology pursuits to block specific pathways, mainly …

l‐Asparaginase (a hydrolase converting l‐asparagine to l‐aspartic acid) was the first
enzyme to be used in clinical practice as an anticancer agent after its approval in 1978 as a …

Conventional anti-cancer therapy involves the use of chemical chemotherapeutics and
radiation and are often non-specific in action. The development of drug resistance and the …

Abstract L-Asparaginase (L-ASNase, EC 3.5. 1.1), an antitumor drug for acute lymphoblastic
leukemia (ALL) therapy, is widely used in the clinical field. Similarly, L-ASNase is also a …

Metabolic differences between normal and cancerous cells have been used as a point of
view for developing anticancer drugs. Some degrading enzymes of certain amino acids …

A virus minimally contains a nucleic acid genome packaged by a protein coat. The genome
and capsid together are known as the nucleocapsid, which has an envelope containing a …

L-asparaginases (EC 3.5. 1.1) are a family of enzymes that catalyze the hydrolysis of L-
asparagine to L-aspartic acid and ammonia. These proteins with different biochemical …

Conventional cancer therapies such as chemotherapy, radiation therapy, and
immunotherapy due to the complexity of cancer have been unsuccessful in the complete …

L-asparaginase, an amidohydrolase that catalyses break down of L-asparagine into aspartic
acid and ammonia, is one of the most prominent biopharmaceuticals. L-asparaginase (LA) …